Antibacterial activity of azithromycin against Brucella melitensis.
In vitro antibacterial activity of the new macrolide azithromycin was tested against 116 strains of Brucella melitensis, isolated from 115 patients in a major tertiary care referral center. Eighty-seven percent of the strains were inhibited by 1.0 mg/l and all the 116 strains by 2.0 mg/l of azithromycin. Comparison was made with tetracycline, gentamicin, trimethoprim-sulfamethoxazole, rifampicin and ciprofloxacin. All the isolates were susceptible to gentamicin, tetracycline, trimethoprim-sulfamethoxazole, rifampicin. One hundred and fifteen of the 115 strains were also susceptible to ciprofloxacin.
Qadri
S M
SM
King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Halim
M A
MA
Ueno
Y
Y
Abumustafa
F M
FM
Postle
A G
AG
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017963:Azithromycin / Q000494:pharmacology*; D017347:Brucella melitensis / Q000145:classification / Q000187:drug effects*; D004338:Drug Combinations; D006801:Humans; D013045:Species Specificity
D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D017963:Azithromycin